Prevention of hyaline membrane disease with plasminogen. A cooperative study.
In a double-blind, randomized study, 500 premature infants were treated with plasminogen or placebo intravenously within 60 minutes of birth. There was a substantial decrease in severe clinical respiratory distress, death caused by hyaline membrane disease, and total mortality in the plasminogen-treated infants as compared to the controls.
D002986:Clinical Trials as Topic; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D005865:Gestational Age; D006801:Humans; D006819:Hyaline Membrane Disease / Q000378:metabolism / Q000517:prevention & control*; D007231:Infant, Newborn; D007275:Injections, Intravenous; D008297:Male; D010958:Plasminogen / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011650:Pulmonary Alveoli / Q000378:metabolism
D005337:Fibrin; D010958:Plasminogen